Sickle cell disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• G6PD 0
• NLRP3 0
• APOL1 0
• CD19 3
• BTK 0
• FGFR 0
• NRF2 0
• SGLT2 1
• CFTR 1
• CXCR4 0
• DMD 1
• GLP-1 0
• HDAC 1
• HMGB1 0
• HTT 1
• JAK 0
• NF1 1
• SMN1 1

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Innovating Sickle Cell Disease Treatment: From Non-Canonical Signaling and Immune Activation to Personalized Targeted Therapies (TARGET-SCD)

  Universite Paris Cite· Paris, France· EU contribution €2,449,320· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Deciphering Inflammatory and Placental Mechanisms of Pre-eclampsia in Sickle Cell Disease (PRECISE)

  Imagine Institut des Maladies Genetiques Necker Enfants Malades Fondation· Paris, France· EU contribution €242,261· until Dec 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  A metabolic-based defense strategy against malaria (KILLBILL)

  Fundacao Gimm - Gulbenkian Institute for Molecular Medicine· Lisboa, Portugal· EU contribution €2,500,000· until Sept 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  CONSORTIUM FOR DEVELOPING REGULATORY CAPACITY FOR CLINICAL TRIALS USING GENE THERAPY PRODUCTS AND STRENGTHENING PHARMACOVIGILANCE IN THE CONDUCT OF CLINICAL TRIALS IN EAST AFRICA (CAPACITY 2023)

  Universidade de Coimbra· Coimbra, Portugal· EU contribution €999,315· until Mar 2027· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Synthetic generation of hematological data over federated computing frameworks (SYNTHEMA)

  Universidad Politecnica de Madrid· Madrid, Spain· EU contribution €6,514,560· until Nov 2026· 10 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 8 running projects, newest first. Listed amounts together: €25.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• CRISPR-Cas Systems 15
• Gene Expression Profiling 7
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 2
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 2
• Magnetic Resonance Imaging 21
• Machine Learning 5
• Deep Learning 3
• Cohort Studies 19
• Genome-Wide Association Study 5

• Sickle cell retinopathy molecular investigation through proteomic analysis of Townes HbSS mice retinas.

  Exp Biol Med (Maywood), Oct 2026

• Proteomic profiling identifies systemic drivers of blood-brain barrier injury in sickle cell disease.

  Blood, Sept 2026

• Plasma Proteome Signatures in Sickle Cell Anemia and the Effect of Hydroxyurea Treatment.

  J Proteome Res, Sept 2026

• Beyond Pain: A Pilot Study of Neurodegenerative and Mitochondrial Pathway Alterations in Sickle Cell Disease Using Platelet Proteomics.

  Med Sci (Basel), Aug 2026

• Loss of energy homeostasis contributes to hepatic damage development in sickle cell disease.

  Mol Metab, Mar 2026

• Proteomic Analysis of Golden Sputum Reveals Pulmonary Complement Activation During Acute Chest Syndrome in Children With Sickle Cell Disease.

  Am J Hematol, Dec 2025

• Resveratrol: Antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patients.

  Int J Mol Med, Feb 2012

See which targets of this disease your abstract mentions, and go to the people working on them.